July 2 (Reuters) - Cartesian Therapeutics ( RNAC ) said

on Tuesday that its experimental immune disorder therapy met the

main goal in a mid-stage trial.

The therapy known as descartes-08 is a chimeric antigen

receptor T-cell therapy, or CAR-T cell therapy, to treat

patients with myasthenia gravis an autoimmune disorder that

causes disabling muscle weakness and fatigue.

The company said 71% of patients in the study showed

significant improvement in symptoms as measured on a disease

severity scale at three months, compared to 25% of patients who

were given a placebo.